Asthma is chronic inflammation of the airways characterized by airway hyper-responsiveness, wheezing, cough, and dyspnea. Asthma affects >350 million people worldwide. The Th2 immune response is a major contributor to the pathophysiology of asthma. Targeted therapy modulating cell signaling pathways can be a powerful strategy to design new drugs to treat asthma. The potential molecular pathways that can be targeted include IL-4-IL-13-JAK-STAT-MAP kinases, adiponectin-iNOS-NF-κB, PGD2-CRTH2, IFNs-RIG, Wnt/β-catenin-FAM13A, FOXC1-miR-PI3K/AKT, JNK-Gal-7, Nrf2-ROS, Foxp3-RORγt, CysLTR, AMP, Fas-FasL, PTHrP/PPARγ, PAI-1, FcɛRI-LAT-SLP-76, Tim-3-Gal-9, TLRs-MyD88, PAR2, and Keap1/Nrf2/ARE. Therapeutic drugs can be designed to target one or more of these pathways to treat asthma.

哮喘是气道的慢性炎症，其特征是气道高反应性、喘息、咳嗽和呼吸困难。哮喘影响全球超过 3.5 亿人。Th2 免疫反应是哮喘病理生理学的主要贡献者。调节细胞信号通路的靶向治疗可以成为设计治疗哮喘新药的强大策略。可靶向的潜在分子途径包括 IL-4-IL-13-JAK-STAT-MAP 激酶、脂联素-iNOS-NF-κB、PGD2-CRTH2、IFNs-RIG、Wnt/β-catenin-FAM13A、FOXC1- miR-PI3K/AKT、JNK-Gal-7、Nrf2-ROS、Foxp3-RORγt、CysLTR、AMP、Fas-FasL、PTHrP/PPARγ、PAI-1、FcɛRI-LAT-SLP-76、Tim-3-Gal- 9、TLRs-MyD88、PAR2 和 Keap1/Nrf2/ARE。可以设计治疗药物来针对这些途径中的一种或多种来治疗哮喘。